Group 1 - UBS report indicates that Kangfang Biopharma (9926.HK) core product AK112 (ivonescimab) shows significant potential in indications beyond non-small cell lung cancer (NSCLC) [1] - In addition to six indications for NSCLC, the company has initiated six Phase III clinical trials covering first-line treatment areas such as cholangiocarcinoma, triple-negative breast cancer, and pancreatic cancer, leading the breadth of indications among similar drugs [1] - Since being included in the national medical insurance directory in January this year, sales of the drug have rapidly increased, and it received approval for a new indication in NSCLC first-line treatment in May [1] Group 2 - UBS expects that through negotiations for medical insurance by 2025, AK112 will further contribute to incremental revenue, raising the peak sales estimates for AK112 in China and globally to 1.2 billion and 14.6 billion USD respectively [1] - The firm reiterates a buy rating and significantly raises the target price from 112.1 HKD to 197.5 HKD [1]

Core Viewpoint - UBS reaffirms a buy rating for Kangfang Biopharma (09926.HK) and significantly raises the target price to HKD 197.5, highlighting the potential of its core product AK112 (ivonescimab) beyond non-small cell lung cancer (NSCLC) [1] Group 1: Product Potential - AK112 shows significant potential in indications beyond NSCLC, with six additional phase III clinical trials initiated covering areas such as cholangiocarcinoma, triple-negative breast cancer, and pancreatic cancer [1] - The breadth of indications for AK112 is noted to be the highest among similar drugs in the market [1] Group 2: Sales Growth and Market Impact - Following its inclusion in the national medical insurance directory in January, AK112 has experienced rapid sales growth [1] - The drug received approval for a new indication in NSCLC as a first-line treatment in May, which is expected to contribute additional revenue through negotiations in the medical insurance sector by 2025 [1] Group 3: Financial Projections - UBS has adjusted the peak sales estimates for AK112 in China and globally to USD 1.2 billion and USD 14.6 billion, respectively [1]

Investment Rating - The report rates the pharmaceutical industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [4][27]. Core Insights - The pharmaceutical sector saw a weekly increase of 3.6%, outperforming the Shanghai Composite Index, which rose by 1.4% [4][5]. - The report highlights the introduction of supportive policies for innovative drugs and high-end medical devices, including a comprehensive support system for innovative drug development, access, usage, and payment [4][12]. - The negotiation for the 2025 National Medical Insurance Drug List has officially started, with plans to include innovative drugs in commercial health insurance for the first time [4][13]. - AstraZeneca and Summit are reportedly negotiating a deal worth over $15 billion for the drug AK112, indicating significant activity in the innovative drug market [4][16]. - The report emphasizes the growth in revenue and licensing deals for innovative drugs, suggesting a trend towards broader market expansion [4]. Market Performance - The pharmaceutical sector's overall valuation stands at 29.8 times PE (2025E), ranking 6th among 31 primary industries [4][11]. - The performance of various sub-sectors includes: - Raw materials (+5.8%) - Chemical preparations (+4.9%) - Other biological products (+8.3%) - Medical devices (-0.2%) [4][7]. Key Events - On July 1, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, outlining 16 specific initiatives [4][12]. - The National Medical Products Administration announced measures to support the innovation of high-end medical devices, focusing on key areas such as medical robots and AI medical devices [4][13]. - Longcheng Gaoxin announced plans to issue H shares and list on the Hong Kong Stock Exchange, enhancing its international brand image [4][15].